NDC 48433-308-01 - Amlodipine Besylate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 48433-308
- Requested NDC
- 48433-308-01
- Package NDCs from labels
- 48433-308-01, 48433-308-10
- Manufacturer
- Safecor Health, LLC
- Effective date
- 2013-01-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Amlodipine Besylate - Safecor Health, LLC | Safecor Health, LLC | 2013-01-01 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| AMLODIPINE BESYLATE | ACTIVE INGREDIENT | 864V2Q084H | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 | |
| AMLODIPINE | ACTIVE MOIETY | 1J444QC288 | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 | |
| CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS | INACTIVE INGREDIENT | L11K75P92J | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO | INACTIVE INGREDIENT | 5856J3G2A2 | AMLODIPINE BESYLATE TABLET [SAFECOR HEALTH, LLC] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Amlodipine and Olmesartan Medoxomil | AMLODIPINE AND OLMESARTAN MEDOXOMIL | Glenmark Pharmaceuticals Inc., USA | 2edf43fb-0755-4ffb-bc38-75a4e2432588 | 2021-02-28 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| Amlodipine besylate and Atorvastatin calcium | AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | Dr. Reddy's Laboratories Inc | abee4a34-89cc-d886-192c-32582ab8f024 | 2021-02-16 | Warnings, Adverse reactions | 864V2Q084H |
| Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | Teva Pharmaceuticals USA, Inc. | 5c128ef2-60a6-40f3-b37f-ee139fe27987 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| MEDULLOSSEINUM PLEX | ARNICA MONTANA, CALCAREA PHOSPHORICA, CALENDULA OFFICINALIS, HYPERICUM PERFORATUM, MEDULLOSSEINUM, PULSATILLA, RUTA GRAVEOLENS, SYMPHYTUM OFFICINALE | Seroyal USA | 22b7eafe-ef76-0677-e054-00144ff88e88 | 2020-10-09 | Warnings | L11K75P92J |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Proficient Rx LP | 9f327d08-7661-4088-b554-2f9a99a113e7 | 2020-10-01 | Warnings, Adverse reactions | 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Cipla USA Inc. | 0c8d6b2f-3e4a-47a2-80e2-a34dcb337555 | 2020-09-09 | Warnings, Adverse reactions | 864V2Q084H |
| AMLODIPINE BESYLATE | AMLODIPINE BESYLATE | Proficient Rx LP | 410aa0a5-43cf-455c-b51d-7dfbc24eee32 | 2020-02-01 | Warnings, Adverse reactions | 864V2Q084H |
| 311b627b-b77d-44bd-ba8a-d59eed27dede | 790129ef-6a1b-45cb-8b02-25fa8a40c2ba | 2019-11-22 | Warnings, Adverse reactions | 790129ef-6a1b-45cb-8b02-25fa8a40c2ba | ||
| Norvasc | AMLODIPINE BESYLATE | PFIZER LABORATORIES DIV PFIZER INC | abd6a2ca-40c2-485c-bc53-db1c652505ed | 2019-01-15 | Warnings, Adverse reactions | 864V2Q084H |
| Telmisartan and Amlodipine | TELMISARTAN AND AMLODIPINE | Mylan Pharmaceuticals Inc. | ca60a4d5-ace7-4889-94ee-e2265fd63811 | 2018-11-14 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| Amlodipine besylate | AMLODIPINE BESYLATE | Aphena Pharma Solutions - Tennessee, LLC | 17e6d552-7528-4597-9498-104cb04f32e7 | 2017-10-25 | Warnings, Adverse reactions | 864V2Q084H |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.